✨ Free AI Report
Aerovate Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Aerovate Therapeutics, Inc.
Company Research

Aerovate Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing drugs for rare cardiopulmonary disease, with primary focus on AV-101, a dry powder inhaled formulation of imatinib for pulmonary arterial ...

Analyst-debate audio for Aerovate Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Aerovate Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Clinical-stage rare disease biotech with challenged lead program but substantial funding and recent strategic merger to sustain...

Read the full analyst-debate transcript →
Industry Orphan Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Aerovate Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Aerovate Therapeutics, Inc. Overview

Pro stress-test →

Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing drugs for rare cardiopulmonary disease, with primary focus on AV-101, a dry powder inhaled formulation of imatinib for pulmonary arterial hypertension (PAH). AV-101 delivers medicine directly to diseased lung tissues while reducing systemic adverse side effects. The company operates in a highly specialized niche within rare disease therapeutics.

Strategic Profile

Pro stress-test →

Aerovate underwent a reverse merger with Jade Biosciences on April 28, 2025, which expanded its operational capacity and platform. The company operates in the pulmonology sector, competing against established players like Gossamer Bio and Corsair Pharma. With a clinical-stage asset and recent merger integration, Aerovate is positioned to advance its lead program through ongoing development.

Competitive Landscape

Pro stress-test →

Top competitors include Gossamer Bio, Actelion, and Corsair Pharma. These companies also focus on rare cardiopulmonary and pulmonary hypertension therapeutics. Aerovate's differentiation lies in its inhaled dry powder approach to imatinib delivery, though clinical efficacy has been questioned by recent trial results.

Industry Context

Aerovate Therapeutics, Inc. operates in Orphan Drugs.

Key facts

Founded: 2018 · Headquarters: Waltham, US · Employees: 4 · Revenue: N/A · Market cap: $483.59M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Aerovate Therapeutics, Inc..

  • Lead program AV-101 experienced clinical setback (June 2024), requiring strategic pivot or program reassessment
  • Recent reverse merger with Jade Biosciences (April 2025) signals integration of complementary assets or capabilities
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2025Reverse merger with Jade Biosciences completed, expanding operational platform
  • June 2024AV-101 reported failure in PAH treatment trial
  • +1 moreTrack every material event for Aerovate Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Aerovate Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Gossamer BioRare pulmonary disease therapeutics→ActelionPulmonary hypertension and rare disease drugs→Corsair PharmaCardiopulmonary disease therapeutics→

Compare Aerovate Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aerovate Therapeutics, Inc. operates in Orphan Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Orphan Drugs research →
NEW · MCP server

Ask your AI assistant about Aerovate Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aerovate Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Aerovate Therapeutics, Inc. do this quarter?”
“Is Aerovate Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Aerovate Therapeutics, Inc. do?+
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing drugs for rare cardiopulmonary disease, with primary focus on AV-101, a dry powder inhaled formulation of imatinib for pulmonary arterial ...
What is Aerovate Therapeutics, Inc.'s Cyborg Score?+
Aerovate Therapeutics, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aerovate Therapeutics, Inc.'s main competitors?+
Named competitors include Gossamer Bio, Actelion, Corsair Pharma. The full competitive landscape is in the AskCyborg report.
How can I get the full Aerovate Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aerovate Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aerovate Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.